JP2023552456A - 治療薬の家畜動物における半減期を増加させるための組成物及びその使用方法 - Google Patents

治療薬の家畜動物における半減期を増加させるための組成物及びその使用方法 Download PDF

Info

Publication number
JP2023552456A
JP2023552456A JP2023534323A JP2023534323A JP2023552456A JP 2023552456 A JP2023552456 A JP 2023552456A JP 2023534323 A JP2023534323 A JP 2023534323A JP 2023534323 A JP2023534323 A JP 2023534323A JP 2023552456 A JP2023552456 A JP 2023552456A
Authority
JP
Japan
Prior art keywords
amino acid
domestic animal
group
acid substitution
position corresponding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023534323A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023552456A5 (https=
Inventor
ブロンディク、ウィリアム
ホーン、ユルゲン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Invetx Inc
Original Assignee
Invetx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Invetx Inc filed Critical Invetx Inc
Publication of JP2023552456A publication Critical patent/JP2023552456A/ja
Publication of JP2023552456A5 publication Critical patent/JP2023552456A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/70—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in livestock or poultry

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023534323A 2020-12-07 2021-12-01 治療薬の家畜動物における半減期を増加させるための組成物及びその使用方法 Pending JP2023552456A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063122365P 2020-12-07 2020-12-07
US63/122,365 2020-12-07
PCT/US2021/061409 WO2022125355A1 (en) 2020-12-07 2021-12-01 Compositions for increasing half-life of a therapeutic agent in livestock animals and methods of use

Publications (2)

Publication Number Publication Date
JP2023552456A true JP2023552456A (ja) 2023-12-15
JP2023552456A5 JP2023552456A5 (https=) 2024-12-09

Family

ID=81848817

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023534323A Pending JP2023552456A (ja) 2020-12-07 2021-12-01 治療薬の家畜動物における半減期を増加させるための組成物及びその使用方法

Country Status (10)

Country Link
US (2) US12103961B2 (https=)
EP (1) EP4255933A4 (https=)
JP (1) JP2023552456A (https=)
KR (1) KR20230128283A (https=)
CN (1) CN117043190A (https=)
AU (1) AU2021397693A1 (https=)
CA (1) CA3201120A1 (https=)
MX (1) MX2023006639A (https=)
TW (1) TW202237641A (https=)
WO (1) WO2022125355A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119730881A (zh) * 2022-08-05 2025-03-28 硕腾服务有限责任公司 牛抗体突变体
KR20250084941A (ko) * 2022-10-07 2025-06-11 조에티스 서비시즈 엘엘씨 돼지 항체 돌연변이체

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005501514A (ja) * 2000-12-12 2005-01-20 メディミューン，インコーポレイテッド 延長した半減期を有する分子ならびにその組成物および用途
JP2008519860A (ja) * 2004-11-12 2008-06-12 ゼンコー・インコーポレイテッド ＦｃＲｎとの変化した結合を有するＦｃ変異体
WO2013081143A1 (ja) * 2011-11-30 2013-06-06 中外製薬株式会社 免疫複合体を形成する細胞内への運搬体（キャリア）を含む医薬
WO2020082048A1 (en) * 2018-10-18 2020-04-23 Kindred Biosciences, Inc. Fc variants with altered binding to neonatal fc receptor (fcrn) for veterinary use

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
ES2142801T3 (es) 1991-03-11 2000-05-01 Univ Georgia Res Found Clonacion y expresion de luciferasa de renilla.
EP0759170B1 (en) 1993-09-10 2008-07-09 The Trustees Of Columbia University In The City Of New York Uses of green fluorescent protein
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
IL129767A0 (en) 1996-12-12 2000-02-29 Prolume Ltd Apparatus and method for detecting and identifying infectious agents
JP2002507410A (ja) 1998-03-27 2002-03-12 プロルーム・リミテッド ルシフェラーゼ、蛍光タンパク質、ルシフェラーゼおよび蛍光タンパク質をコードする核酸および、診断、高処理スクリーニングおよび新規アイテムにおけるその使用
WO2005047327A2 (en) * 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
US20060074225A1 (en) * 2004-09-14 2006-04-06 Xencor, Inc. Monomeric immunoglobulin Fc domains
JP6322411B2 (ja) * 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
US20130129727A1 (en) 2011-11-17 2013-05-23 Nanjingjinsirui Science & Technology Biology Corporation Methods and systems for increasing protein stability
NZ631007A (en) * 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
DK3484514T3 (da) * 2016-05-23 2024-01-29 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
WO2018151841A1 (en) * 2017-02-17 2018-08-23 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
CA3120566C (en) * 2017-04-07 2023-12-12 Kookmin University Industry Academy Cooperation Foundation Antibody fc variants for increased blood half-life
CN113544153B (zh) * 2019-01-03 2024-12-10 因外泰克斯公司 用于增加治疗剂在犬中的半衰期的组合物及使用方法
CN120590527A (zh) * 2020-05-11 2025-09-05 因外泰克斯公司 用于增加治疗剂在犬中的半衰期的组合物和使用方法
KR20230038522A (ko) * 2020-07-10 2023-03-20 인베티엑스 인코포레이티드 고양이에서 치료제의 반감기를 증가시키기 위한 조성물 및 사용 방법
JP2023551194A (ja) 2020-11-20 2023-12-07 ゾエティス・サービシーズ・エルエルシー ウシ科動物抗体バリアント

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005501514A (ja) * 2000-12-12 2005-01-20 メディミューン，インコーポレイテッド 延長した半減期を有する分子ならびにその組成物および用途
JP2008519860A (ja) * 2004-11-12 2008-06-12 ゼンコー・インコーポレイテッド ＦｃＲｎとの変化した結合を有するＦｃ変異体
WO2013081143A1 (ja) * 2011-11-30 2013-06-06 中外製薬株式会社 免疫複合体を形成する細胞内への運搬体（キャリア）を含む医薬
WO2020082048A1 (en) * 2018-10-18 2020-04-23 Kindred Biosciences, Inc. Fc variants with altered binding to neonatal fc receptor (fcrn) for veterinary use

Also Published As

Publication number Publication date
US20250197478A1 (en) 2025-06-19
WO2022125355A1 (en) 2022-06-16
US12103961B2 (en) 2024-10-01
CA3201120A1 (en) 2022-06-16
CN117043190A (zh) 2023-11-10
AU2021397693A1 (en) 2023-07-13
MX2023006639A (es) 2023-08-16
TW202237641A (zh) 2022-10-01
EP4255933A4 (en) 2025-07-23
US20220177549A1 (en) 2022-06-09
EP4255933A1 (en) 2023-10-11
KR20230128283A (ko) 2023-09-04

Similar Documents

Publication Publication Date Title
US20230279118A1 (en) Compositions for increasing half-life of a therapeutic agent in canines and methods of use
US12344650B2 (en) Compositions for increasing half-life of a therapeutic agent in felines and methods of use
JP7832123B2 (ja) 治療薬のイヌにおける半減期を増加させるための組成物及びその使用方法
US20250197478A1 (en) Compositions for increasing half-life of a therapeutic agent in livestock animals and methods of use
RU2828219C2 (ru) Композиции для увеличения периода полужизни терапевтического средства у собак и способы применения
HK40102570A (zh) 延长治疗剂在家畜动物中的半衰期的组合物和使用方法
HK40127007A (zh) 用於增加治疗剂在犬中的半衰期的组合物及使用方法
HK40128509A (zh) 用於增加治疗剂在犬中的半衰期的组合物和使用方法
HK40085105B (zh) 用於延长治疗剂在猫科动物中的半衰期的组合物和使用方法
HK40085105A (en) Compositions for increasing half-life of a therapeutic agent in felines and methods of use
HK40063007B (zh) 用於增加治疗剂在犬中的半衰期的组合物及使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260206

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260428